S. Charabi et al., GROWTH OF VESTIBULAR SCHWANNOMAS - IN-SITU MODEL EMPLOYING THE MONOCLONAL-ANTIBODY KI-67 AND DNA FLOW-CYTOMETRY, The American journal of otology, 17(2), 1996, pp. 301-306
Vestibular schwannoma (VS) growth potentials were studied in an in sit
u model, in which the cycling cellular fraction was determined immunoh
istochemically by applying the mouse monoclonal Ki-67 antibody, and th
e tumor ploidy was estimated by DNA flow cytometry in a consecutive se
ries of 124 VSs. The tumors were classified according to the average n
umber of positively stained nuclei in 10 high-power fields into three
groups: 28 highly (>10), 33 moderately (>5-10) and 63 low proliferatin
g (less than or equal to 5). The intratumoral proliferative variation
was studied in 10 tumors. Only slight variation in the number of the p
ositively stained nuclei were observed. Six of seven tumors removed be
cause of macroscopically documented growth by computed tomography (CAT
) scan were moderately or highly proliferative. Proliferation of VS wa
s correlated to prospectively registered clinical data. A statisticall
y significant relation was found between VS proliferation and the pred
iagnostic duration of symptoms (p = 0.0001). The proliferative status
was unrelated to age, sex, and tumor size. Flow-cytometric determinati
on of DNA index of the 124 tumors revealed 12 tetraploid (DNA index =
2), 110 diploid (DNA index = 1) and two nondiploid tumors. A statistic
ally significant relation was noted between tumor ploidy and prolifera
tion status expressed by Ki-67 (p = 0.024). The tetraploid tumors show
ed significantly lower proliferation compared with the diploid tumors.
Tumor ploidy was statistically unrelated to age, sex, tumor size, and
duration of symptoms. The results of this study provide a link betwee
n the immunohistochemical, flow cytometric findings, and clinical data
, which could probably be relevant in identifying patients at risk for
rapid tumor growth and tumor recurrences, because a rapid test for ce
ll proliferation is now available.